Laboratory tests - Sample Testing
Various instruments and techniques are used to examine the patient's blood, urine, feces, pleural effusion, ascites, and cerebrospinal fluid, including biochemical tests, immune tests, and bacterial tests.
Cancer patients also undergo regular blood tests during treatment to monitor their response to treatment and overall health, such as observing red blood cell, white blood cell, and platelet levels, cancer markers, and liver and kidney function, to ensure that the patient's body can withstand the effects of treatment.
Related Articles
A new treatment option for patients with advanced cancer! It is recommended to arrange an IHC immunohistochemical test for HER2 protein expression as soon as possible
On April 5, 2024, the FDA approved fam-trastuzumab deruxtecan-n
A new choice for the treatment of EGFR mutant lung cancer! The combined regimen of first-line Amivantamab and Lazertinib increases the survival period!
On August 19, 2024, the U.S. Food and Drug Administration (FDA) approved the combination therapy of lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), and the FDA-approved test with EGFR exon 19 deletion or deletion. Mutation in the exon 21 L858R gene.
The new American drug AU-007 treats advanced solid tumors, and the tumor shrinks by 20% in the 8th week of treatment!
Recently, the American company Aulos Bioscience announced the results of the initial clinical trial of the new drug AU-007, 1 black
The resolution rate of Enhertu's treatment of patients with brain metastases of HER2-positive breast cancer reached 73.3%!
About 50% of patients with metastatic HER2-positive breast cancer will have brain metastasis. In recent years, the emergence of targeted therapy has significantly prolonged the survival of breast cancer patients.
Repotrectinib, a new lung cancer drug in the United States, was approved, and 79% of patients' tumors shrank significantly!
On November 15, 2023, the U.S. FDA approved oral tyrosine kinase inhibitor (TKI) Augtyro (repotrec).
Xtandi is approved by the FDA for the treatment of patients with this type of prostate cancer (nmCSPC)
On November 16, 2023, Pfizer and Astellas jointly announced that their prostate cancer drug Xtandi (Enzalutamide) has been approved.
Doctor Updates
Headline Daily_genic testing to see through the etiology of lung cancer, matching precision drugs, first-line treatment to help improve the efficacy
Headline Daily_genic testing to see through the etiology of lung cancer, matching precision drugs, first-line treatment to help improve the efficacy
AM730_MET targeted treatment for lung cancer improves chance of remission
AM730_MET targeted treatment for lung cancer improves chance of remission
Headlinedailynews_medicineate_specific-drug combination therapy rekindles the hope of patients with advanced EGFR lung cancer _ St. James Subsidy Program to help patients have their own medicines
Headlinedailynews_medicineate_specific-drug combination therapy rekindles the hope of patients with advanced EGFR lung cancer _ St. James Subsidy Program to help patients have their own medicines
Headline Daily News_the failure of TACE surgical treatment in patients with liver cancer_ Switching to targeted drugs can help control the condition
Headline Daily News_the failure of TACE surgical treatment in patients with liver cancer_ Switching to targeted drugs can help control the condition
Progress in the therapeutic effect of new drugs, be prepared to reduce vomiting and stuffy after chemotherapy
Progress in the therapeutic effect of new drugs, be prepared to reduce vomiting and stuffy after chemotherapy